Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib vs Sorafenib in Advanced RCC
NCT01030783Phase 3Completed
- Sponsor
- AVEO Oncology
- Start
- Dec 2009
- Primary completion
- Jul 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 16
01
Overview
A Phase 3 trial of tivozanib in renal cell carcinoma (RCC), sponsored by AVEO Oncology. Started Dec 2009; status: completed.
02
Drugs
tivozanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01030783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01030783.